The downgrade to Neutral suggests that UBS sees limited upside potential or increased risk in Revvity's stock, which could lead to a short-term negative impact on the stock price. However, the increase in the price target to $125 indicates a positive view on the company's value, which could counterbalance the negative sentiment from the downgrade. The mixed signals may result in a neutral short-term impact as the market digests both pieces of information.